Since the Medtronic-Hall heart valve became available for insertion in 1977, the prosthesis has enjoyed growing popularity because of its excellent hemodynamic performance, superb durability, and acceptably low incidence of late valve-related complications. The purpose of this review is to assess the global clinical performance of this prosthesis to date.
This review of the clinical experience with the Medtronic-Hall valve prosthesis will be directed at three methods of evaluation: 1. Experience with valve implantation techniques and their results 2. Assessment of hemodynamic performance in vivo 3. Late follow-up of valve-related complications and their consequences
Material and methods
All the English-language literature concerning the Medtronic-Hall valve published during the last 14 years has been reviewed.
To assist in the assessment of the results of valve implantation techniques, the Heart Valve Division of Medtronic, Inc., has provided the annual incidence of disc impingements reported to the company and the United States Food and Drug Administration.
Many of the clinical studies which purport to assess the clinical hemodynamic performance of the valve in vivo suffer from inappropriately combining valve sizes or containing incomplete hemodynamic determinations that focus only on transvalve gradients without reference to cardiac index. Therefore, the studies chosen reflect those which avoid these complications.
Prior to the recent publication of the consensus guidelines for reporting morbidity and mortality after cardiac valvular operations [6] , standard definitions and statistical methods to assess complications were lacking, and therefore interinstitutional comparison of results with cardiac valvular prostheses was fraught with hazard. Recently I reviewed the experience with the four mechanical cardiac valvular prostheses currently available in the United States [I] . In performing that review articles were selected which had reasonably standard definitions of complications, separated the results of evaluation between aortic and mitral valve positions, and provided enough information that the patient-years of follow-up were either reported or could be accurately approximated.
Because of the nonuniformity in utilizing actuarial event-free rates at comparable intervals, the review was forced to stress linearized complication rates. The experience with the Medtronic-Hall valve, one of the valves studied in that report, is included in this long-term evaluation and has been updated to include publications about the prosthesis in the subsequent years and also by adding the updated experience with the Medtronic-Hall valve from the Massachusetts General Hospital.
Between October, 1983 and September, 1990, 263 operations were performed at the Massachusetts General Hospital during which a Medtronic-Hall cardiac valvular prosthesis was inserted. From this total number of operations patients with isolated aortic and mitral valve prostheses were selected. Specifically included were patients who had concomitant coronary artery bypass grafting, other valvular repair, left ventricular aneurysm resection, left ventricular myomectomy or ascending aortic aneurysm surgery. Excluded from the study were patients who had placement of more than one Medtronic-Hall prosthesis or patients who already had another prosthetic heart valve in place which was retained at the time of the operation. Table 1 contains information about some of the clinical features distinguishing the aortic and mitral valve replacement groups. Complete follow-up of these patients was obtained as of April, 1991 for a mean follow-up of 41 months, totalling 433 patient-years of follow-up in the aortic valve replacement group and 277 patientyears of follow-up in the mitral valve replacement group. For the follow-up of our patient group, definitions of valve-related complications and their consequences were those published in the consensus guidelines [6] , and both actuarial event-free and linearized rates were calculated.
For each valve-related complication and its consequence according to aortic and mitral valve position the cumulative experience from the appropriate references is reported, and from these a composite linearized rate has been generated. The composite linearized rate is the total incidence of that complication divided by the total available patient-years of follow-up from all of the studies reporting that complication.
Results

Implantation experience
Several unique design features were incorporated in the Medtronic-Hall valve in hopes of achieving excellent hemodynamic performance and with a low incidence of late valve-related complications. Of particular importance are the wide opening angle of the disc, which demands that the surgeon ensure complete disc mobility after the valve has been seated. This important aspect of valve insertion is facilitated by the ability of the disc and housing to rotate within the sewing ring. In addition the disc occludes at the equator of the valve to provide maximal orifice area, but this feature requires that no suture or intracardiac tissue be allowed to prolapse across the housing and impede the opening and closing of the disc. Finally, the disc is coated with pyrolytic carbon, an extremely durable and biocompatible material, which, however, is susceptible to fracture if it is heavily scarred or scratched during valve insertion. Thus the specific design features of the Medtronic-Hall valve, which are attempts to maximize its performance, impose upon the cardiac surgeon the requirement for careful attention to implantation techniques to achieve the best results. Unfortunately, in the early experience of the Medtronic-Hall valve careful understanding of the design features of the prosthesis and the attention to the details of implantation techniques required by those features were not always uniform, leading to some reports of suboptimal valve performance, often related to oversizing, improper disc orientation, or the retention of suture or tissue fragments that impeded disc mobility. Although it may be tempting for the cardiac surgeon to impugn the design features of the Medtronic-Hall valve when implant complications occur, in virtually all cases the problem is not related to the prosthesis but to the insertion technique.
There are several very important tenets that must be followed when inserting a Medtronic-Hall valve: 1. Never oversize the prosthesis. 2. Always ensure full disc mobility. 3. Never scratch the pyrolytic-carbon-coated disc or valve housing. 4. Debride all mobile native valve fragments. 5. Trim all ends of implantation sutures short. With careful attention to education of the cardiac surgeon concerning these principles, and as experience with the prosthesis was gained, the incidence of valve implantation complications has diminished considerably ( Fig. 1 ). Thus in 1989 the incidence of impingements as a percentage of valve implantations in the United States had fallen to 0.2%.
Hemodynamic performance
Obviously a critical determinant of the efficacy of a mechanical cardiac valvular prosthesis is its ability to provide as large a functional valve area for a given annular size as possible and at the same time as small a degree of regurgitation as possible.
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Early assessments of the hemodynamic performance of mechanical valves required invasive catheterization to determine transvalve gradients and cardiac output. In the early experience with the prosthesis both intraoperative and postoperative invasive hemodynamic studies demonstrated good performance of the Medtronic-Hall valve, with discharge coefficients and performance indices that were comparable to those of other prostheses [7, 11, 121 . One subsequent study done on a very small number of mitral valves of one size found poorer discharge coefficients and performance indices when compared to certain other prostheses [8] . The reported gradients and functional valve areas in this study were importantly different from previous larger studies of that valve size.
More recently the use of Doppler echocardiography has become an accepted noninvasive method to assess the function of artificial heart valves. One study that serves as a benchmark for reporting mechanical valves is that reported by Tatineni et al. [14] , who are currently pursuing an ongoing prospective, randomized comparison of the St Jude Medical and Medtronic-Hall valves. The hemodynamic results of that study demonstrate that in clinical usage there is essentially no difference between the two prostheses in terms of rest or exercise transvalve gradients or functional valve area.
Valvular regurgitation in mechanical cardiac valvular prostheses is composed of two components. The dynamic regurgitant fraction is that portion of regurgitation that occurs before the occluder becomes seated. The discs of modern low-profile prostheses close very rapidly -although in the case of bileaflet prostheses occasionally asynchronously -particularly in comparison to ball-cage prostheses, where the significant inertia of the ball slows closure. The second component of valvular regurgitation is static leak rate. All mechanical cardiac valvular disc prostheses have engineered into their design some degree of static leak to help wash the components free of microthrombi. The regurgitant fraction of the MedtronicHall valve, according to information from Medtronic, Inc., varies from about 5% in 20-mm prostheses to about 9% in 29-mm prostheses.
Late valve-related complications and consequences
Currently attempts to find complete, valid assessments of mechanical cardiac valvular prostheses performed according to the recently published consensus guidelines are essentially futile. Acknowledging the fact that linearized complications rates are only valid when the hazard function of a complication is constant throughout the period of follow-up and that actuarial event-free rates are more statistically reliable determinants of the function of a prosthesis, the virtually uniform absence of actuarial event-free rates at comparable intervals in comparable patient populations in the published literature forces this review to focus on linearized complication rates. Thus what follows is a summary of the published literature on the late complications and their consequences, as defined by the consensus guidelines, for the Medtronic-Hall valve, separated as to aortic and mitral position. Although this combined experience represents follow-up in over 3700 patients, this total amounts to less than 4% of the Medtronic-Hall valves implanted. (The published experience is unfortunately similarly limited for virtually all mechanical cardiac valvular prostheses [l] Medtronic-Hall aortic and mitral prosthesis. The incidence from our own institution is quite high; this is in part related to our adherence to the strict definitions of the consensus guidelines and also because the anticoagulation policy among our cardiologists frequently achieves a greater degree of anticoagulation than is needed. Not unexpectedly, the poorly anticoagulated population of patients from South Africa has a very low incidence of anticoagulant-related bleeding.
Prosthetic valve endocarditis. Tables 10 and 11 report the experience with prosthetic valve endocarditis for Medtronic-Hall aortic and mitral valve prostheses.
Reoperation. Tables 12 and 13 report the published experience with the incidence of reoperation in MedtronicHall aortic and mitral prostheses. While the reoperative incidence from the South African populations may be in part explained by the previously mentioned noncompliant patient populations and their increased incidence of thromboembolism and thrombosis, it is unclear why the two reports from the United States show such variation, particularly for valves in the aortic position.
Finally, Table 14 demonstrates the composite expetience with late valve-related complications and their consequences for the Medtronic-Hall valve in the aortic and mitral positions. 
Conclusion
A review of the reported global experience with the Medtronic-Hall cardiac valvular prosthesis demonstrates first that the unique design features require careful attention of the cardiac surgeon during insertion to avoid oceluder malfunction, and that the incidence of insertion problems has been markedly improved due to extensive efforts to educate surgeons and to surgeons' growing experience with the prosthesis. Secondly, clinical assessment of the valve has documented hemodynamic performance which is as good or better than that of other mechanical cardiac valvular prostheses. Finally, long-term follow-up of the Medtronic-Hall prosthesis has demonstrated an acceptably low incidence of late valve-related complications and their consequences. Dr. C. Atkins (Bosron, Mass., USA). Unfortunately, most reports in the literature do not conform to the guidelines. Hopefully, in the future we will be able to compare actuarial event-free rates, but we have been forced to focus on linear rates. In addition to lacking actuarial values, very few researchers discuss the status of anticoagulation in their patients at the time of thromboembolism.
Our report has not yet been published, but it will contain anticoagulation levels.
Sir Barratt-Boyea (Auckland, New Zealand). Dr. Akins, of the data you presented, virtually none appear to have any statistical signiticance. Do any of the differences between valves have any statistical significance?
Dr. Akios: We have not reported statistical significance because the data are from studies that are variable and often noncontrolled, and thus cannot be verified. For example, so little data are available on the Omniscience valve that it would not be fair to compare it to another group of prostheses for which there were several reports or a much larger experience with many patient-years of follow-up. To import statistical significance might be misleading, and therefore I might be guilty of weighting some incorrect evidence. However, your point is very well taken.
Sir Barratt-Buyes: Statistical significance is still the recognized method of analysis. When we gather material we agree that the base material may differ, but the larger the study, the more likely statistical significance will be clarified. In proving significance simply by providing confidence limits, those limits indicate the size of the study, and that must be taken seriously. Dr. Akins: These patient populations are totally disparate, ranging from a noncompliant patient population in the third-world portions of South Africa to the American or European experience. Certain population factors may contribute so heavily that drawing significance might give certain valves a statistical advantages. Dr. Hall: There is a great need for randomized studies of these valves. One paper from Dr. Burner in St. Louis, although small, is based on a randomized study. They found no statistical differences, but in many measurements the Medtronic-Hall valve was numerically better than the St Jude Medical. To the best of my knowledge we were the first to do a randomized study, in 1971. Therefore I hope that others will do randomized studies.
Dr. B. de Mol (Amsterdam, The Nether/an&). I am a cardiac surgeon from Amsterdam and a safety and products liability consultant for the Technical University of Delft. We conducted special studies on the Bjiirk-Shiley problem, and, as reported in the Earn As You Learn report from John Dingle, the FDA ruled on the basis of materials analysis that thrombogenicity was a superior characteristic of this valve. The studies based on materials analysis are very informative and useful; however, there are many deficiencies in evaluation of valve performance. The valves are already performing so well that many incidents are relatively rare; thus, can materials analysis be considered an appropriate instrument for comparing valves? Is it really possible to make fair comparisons to new valves, especially when the follow-up is small and incomplete? It is clear that randomized studies must be done, but is it imperative? Can we wait. and continue as we are?
Dr. Akk
I would certainly not submit the data I presented as a standard against which others are to be compared. I am simply providing the information available in the literature. However, we eliminated the reports of patient survival because we considered survival more disease-and patient-related, rather than valve-related. In addition, some of the valve-related complications were heavily affected by patient populations, particularly in noncompliant third-world populations, redo populations, older patients who already had a high incidence of atria1 fibrillation, and multiple reoperations. In comparing these populations to first-time operations in otherwise healthy 40-year-olds from populations that are operated on largely for rheumatic fever, the patient-related factors influence the data. The lack of consideration of these issues in the data from the literature illustrates how deficient reporting has been.
Dr. de Mel:
The definition of a complication is not merely a semantic question but also a technical question. At meetings such as this we must discern whether complications are valve-related or more patient-related. In addition, the events are rare. Much larger, consistent studies are required to reach any level of significance. Dr. Hall: Someday there will be statistically significant differences. However, as long as there is no structural breakdown, this valve could be advantagous.
Dr. H. Huysmans (Leiden, The Netherlundr).
The issue of the noise produced by the mechanical valve is very rarely addressed. We recently studied this problem in the Netherlands, and one very interesting patient with endocarditis had three operations and three different sets of valves: Bjiirk-Shiley, Duromedics, and MedtronicHall. This patient felt that the Medtronic-Hall valves made the most noise. Do you have any data on that? Dr. Hall: That is true. The Medtronic-Hall valve is slightly noisier than some other valves. One of my patients with endocarditis had his first tissue valve implant replaced with a Medtronic-Hall valve. However, he returned a year later and demanded a tissue valve. It was very peculiar, because he was feeling well and in every respect seemed to be healed. We refused to operate on him again because there was no significant rationale.
